title: Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.
abstract: An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.
authors.affiliation: Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, Scotland, United Kingdom. f.odds@abdn.ac.uk
authors.forename: F C
authors.initials: FC
authors.lastname: Odds
authors.forename: M
authors.initials: M
authors.lastname: Oris
authors.forename: P
authors.initials: P
authors.lastname: Van Dorsselaer
authors.forename: F
authors.initials: F
authors.lastname: Van Gerven
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000097:blood / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy*; D003453:Cryptococcosis / Q000188:drug therapy*; D003455:Cryptococcus neoformans / Q000187:drug effects; D004195:Disease Models, Animal; D006168:Guinea Pigs; D017964:Itraconazole / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole